Climb Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Climb Bio şirketinin toplam hissedar öz sermayesi $222.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $226.0M ve $3.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$223.14m
Eşitlik	US$222.28m
Toplam yükümlülükler	US$3.74m
Toplam varlıklar	US$226.02m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Nov 18

Recent updates

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Sep 23

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Feb 01

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

Jun 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CLYM 'nin kısa vadeli varlıkları ( $226.0M ) kısa vadeli yükümlülüklerini ( $3.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: CLYM un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CLYM borçsuzdur.

Borcun Azaltılması: CLYM son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan CLYM mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: CLYM kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 0.9 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Climb Bio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Recent updates

Climb Bio, Inc. Present Additional Data from the Completed Pmn Trial and Share Clinical Data from A Single Patient with Minimal Change Disease (Mcd) Treated with Budoprutug

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Eliem Therapeutics, Inc. Announces Executive Changes

Eliem Therapeutics, Inc. (NasdaqGM:ELYM) completed the acquisition of Tenet Medicines, Inc. from RA Capital Management, L.P. and others.

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics, Inc. announced that it has received $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

Eliem Therapeutics, Inc. Announces Management Changes

Eliem Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Eliem Therapeutics, Inc. announced that it expects to receive $119.955003 million in funding from RA Capital Management, L.P., Deep Track Capital, LP, Boxer Capital LLC, Samsara BioCapital LLC, Janus Henderson Investors US LLC

New major risk - Share price stability

Eliem Therapeutics, Inc. and Tenet Medicines, Inc. Announces Management and Organization Changes

Insufficient new directors

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

New minor risk - Shareholder dilution

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. Announces the Resignation of Leone Patterson from the Board of Directors

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

Price target decreased to US$6.00

Eliem Therapeutics, Inc. Provides Update on Pipeline Progress

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics, Inc. Provides ETX-810 Program Update

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

Eliem Therapeutics, Inc. Announces Last Patient Completed Dosing in Phase 2A Study of ETX-810 in Patients with Lumbosacral Radicular Pain

Eliem Therapeutics, Inc.(NasdaqGM:ELYM) dropped from Russell 2500 Value Index

Eliem Therapeutics Reports Results from its Phase 2A Clinical Trial Investigating ETX-810 for the Treatment of Diabetic Peripheral Neuropathic Pain and Provided an Update on the Status of the ETX-155 Clinical Program in Epilepsy and Depression

Eliem Therapeutics, Inc., Annual General Meeting, May 19, 2022

Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

High number of new directors

High number of new and inexperienced directors

Eliem Therapeutics, Inc. has completed an IPO in the amount of $80 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin